# In vivo Core

> **NIH NIH U19** · UNIVERSITY OF WISCONSIN-MADISON · 2020 · $620,620

## Abstract

Project Summary
Antimicrobial innovation by larger pharmaceutical companies has slowed while an epidemic of antimicrobial-
resistant infections surges, threatening the public health. The overarching goal of the Wisconsin Antimicrobial
Drug Discovery and Development Center is to develop therapeutic countermeasures to tackle the antimicrobial
resistance crisis. Based upon our preliminary data, we hypothesize that natural product exploration of symbiotic
environments using complementary cutting-edge approaches will provide a new paradigm for discovery of novel
antimicrobials targeting drug resistant infections. The Center proposes innovative conceptual and technical
advances to overcome critical bottlenecks identified in traditional antimicrobial drug discovery platforms. The
success of this endeavor is dependent upon the ability to predict antimicrobial effectiveness of the symbiotic
natural products in patients. The In vivo Core will assess the in vivo microbiologic effectiveness, mammalian
safety, pharmacokinetics and pharmacodynamics of promising novel natural product scaffolds from each
Project (1, 2, 3) in the Center. The Core uses clinically relevant murine infection models with each of the
target, drug-resistant pathogens – Gram negative bacteria and fungi. The results from these Core activities
will predict which compounds with promising in vitro activity against drug -resistant pathogens are likely to
progress to a clinically useful antimicrobial drug. The core services will also provide data that answer the
question: which of the novel discovery approaches employed by our three CETR projects best delivers lead
antimicrobial compounds. Elucidation of optimal discovery strategies will yield a transformative and sustained
impact on the development of new drugs.

## Key facts

- **NIH application ID:** 9868273
- **Project number:** 5U19AI142720-02
- **Recipient organization:** UNIVERSITY OF WISCONSIN-MADISON
- **Principal Investigator:** David R Andes
- **Activity code:** U19 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $620,620
- **Award type:** 5
- **Project period:** — → —

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9868273

## Citation

> US National Institutes of Health, RePORTER application 9868273, In vivo Core (5U19AI142720-02). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/9868273. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*